GlycoMimetics, Inc. (GLYC) Can’t Be More Hot. Just Reaches All-Time High

February 15, 2018 - By Linda Rogers

Investors sentiment decreased to 1.08 in Q3 2017. Its down 0.83, from 1.91 in 2017Q2. It dived, as 13 investors sold GlycoMimetics, Inc. shares while 11 reduced holdings. 5 funds opened positions while 21 raised stakes. 28.80 million shares or 2.36% less from 29.49 million shares in 2017Q2 were reported.
The New York-based Morgan Stanley has invested 0% in GlycoMimetics, Inc. (NASDAQ:GLYC). Wellington Gp Llp accumulated 3.49 million shares. Endurant Cap Mgmt L P accumulated 17,607 shares. Baker Bros Advsrs Ltd Partnership stated it has 563,312 shares or 0.06% of all its holdings. Ameriprise Inc invested in 0% or 97,460 shares. Moreover, Citadel Advsrs Ltd Liability Company has 0% invested in GlycoMimetics, Inc. (NASDAQ:GLYC) for 58,422 shares. Barclays Public Limited Liability Corp holds 0% in GlycoMimetics, Inc. (NASDAQ:GLYC) or 31,669 shares. Deutsche National Bank & Trust Ag has 0% invested in GlycoMimetics, Inc. (NASDAQ:GLYC) for 259,789 shares. 66,764 are owned by Bridgeway Mgmt. Thompson Davis And owns 750 shares. Parametric Ltd Co accumulated 77,056 shares. Perigon Wealth Ltd Liability Co has 0% invested in GlycoMimetics, Inc. (NASDAQ:GLYC) for 100 shares. Susquehanna Intl Group Llp, a Pennsylvania-based fund reported 116,629 shares. Columbus Circle Investors holds 201,980 shares. Bancorp Of Mellon Corporation accumulated 0% or 93,769 shares.

Since September 18, 2017, it had 0 buys, and 2 selling transactions for $56,020 activity.

The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) reached all time high today, Feb, 15 and still has $26.99 target or 6.00 % above today’s $25.46 share price. This indicates more upside for the $874.24M company. This technical setup was reported by If the $26.99 PT is reached, the company will be worth $52.45 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 3.33% or $0.82 during the last trading session, reaching $25.46. About 499,834 shares traded. GlycoMimetics, Inc. (NASDAQ:GLYC) has risen 81.25% since February 15, 2017 and is uptrending. It has outperformed by 64.55% the S&P500.

Analysts await GlycoMimetics, Inc. (NASDAQ:GLYC) to report earnings on March, 7. They expect $-0.26 EPS, up 27.78 % or $0.10 from last year’s $-0.36 per share. After $-0.24 actual EPS reported by GlycoMimetics, Inc. for the previous quarter, Wall Street now forecasts 8.33 % negative EPS growth.

GlycoMimetics, Inc. (NASDAQ:GLYC) Ratings Coverage

Among 5 analysts covering GlycoMimetics (NASDAQ:GLYC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GlycoMimetics had 16 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Tuesday, December 12. The firm has “Buy” rating given on Tuesday, September 12 by Jefferies. The firm has “Buy” rating given on Wednesday, November 1 by Roth Capital. Stifel Nicolaus maintained GlycoMimetics, Inc. (NASDAQ:GLYC) on Tuesday, June 6 with “Buy” rating. The stock has “Buy” rating by Roth Capital on Thursday, February 8. The firm has “Buy” rating given on Tuesday, October 3 by SunTrust. As per Tuesday, July 26, the company rating was initiated by SunTrust. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, August 3. The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) has “Buy” rating given on Monday, October 23 by Roth Capital. As per Monday, August 10, the company rating was upgraded by Zacks.

Another recent and important GlycoMimetics, Inc. (NASDAQ:GLYC) news was published by which published an article titled: “GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup …” on February 08, 2018.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $874.24 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.